In this dataset, structural valve deterioration covers claims around how prosthetic heart valves fail mechanically or biologically over time, and the countermeasures for it. That includes leaflet calcification, anti-calcification surface treatments, accelerated wear testing protocols used to simulate years of valve cycling, and the hemodynamic or clinical markers used to justify reintervention. It does not primarily cover unrelated valve failure modes like infection or paravalvular leak unless those claims also touch durability or calcification language.

One assignee holds 115 of the 225 records in scope, well ahead of the rest of the 17 ranked companies — fifth place holds only 5 records and tenth place holds 4. That gap means the core device and treatment claims are concentrated with a single commercial filer, while the remaining ranked assignees, a mix of other device makers and academic or clinical institutions, hold narrower, more specific positions.

Filing peaked at 25 records in 2017 and has fallen since, with the 2021-to-2024 span alone showing a drop from 10 to 2 filings, an 80% decline. 2024 is the most recent year that can be treated as complete; 2025 and 2026 numbers are still filling in because publication typically lags filing by about 18 months, so it is too early to call the current trajectory a continued decline versus a reporting gap.

The technology composition skews heavily toward A61F implant and prosthesis claims, which cover 88.0% of the 225 records, while material analysis and testing (G01N, 3.1%), plastics shaping (B29C, 1.8%) and layered laminates (B32B, 1.8%) are comparatively thin. That imbalance suggests more room in manufacturing, testing-rig and materials-science claims around durability than in claims on the valve device itself, where one filer already holds a large share of the record set.

US10610616B2, assigned to The Regents of the University of California, claims a heart valve leaflet built from a thermoplastic polyurethane mesh tuned to match native leaflet stiffness, optionally seeded with one to three layers of cultured cells on each side, combined with a valve frame. Anyone working on synthetic or hybrid tissue-engineered leaflets using a comparable mesh-plus-cell-seeding structure should review its specific claim scope directly, since the citation record shows it sits among the more heavily cited filings in this space. Designing around it would likely mean varying the mesh material class, the cell-seeding architecture, or dropping the frame integration described in the claims.